Cole Pinnow's most recent trade in Cogent Biosciences Inc was a trade of 214,000 Common Stock done . Disclosure was reported to the exchange on Dec. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 214,000 | 311,450 (1%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.45 per share. | 17 Dec 2025 | 94,800 | 216,650 (0%) | 0% | 39.5 | 3,739,860 | Common Stock |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 50,000 | 97,450 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 7.60 per share. | 14 Jan 2025 | 43,750 | 45,848 (0%) | 0% | 7.6 | 332,413 | Common Stock |
| Cogent Biosciences Inc | Cole Pinnow | Chief Commercial Officer | 25 May 2024 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) |